CTOs on the Move

Unigene Laboratories

www.unigene.com

 
Unigene Laboratories, Inc. (Unigene) is a biopharmaceutical company engaged in the research, production and delivery of small proteins, referred to as peptides, for medical use. The Company has a manufacturing technology for producing many peptides
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.unigene.com
  • 110 Little Falls Rd
    Fairfield, NJ USA 07004
  • Phone: 973.265.1100

Executives

Name Title Contact Details

Similar Companies

G-Biosciences/ Genotech

G-Biosciences/ Genotech is a Maryland Heights, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IDM Pharma

IDM Pharma is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medrad

MEDRAD, Inc. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems,

Atomwise

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.

Inipharm

At Inipharm, we`re building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease. Inipharm`s lead program is focused on small-molecules to target the activity of HSD17B13, a highly validated, genetically defined target for multiple severe liver and related diseases.